The pathway

The canonical lipolysis cascade runs as follows: adrenergic agonist (norepinephrine, epinephrine) binds β-adrenergic receptor on the adipocyte surface. The receptor activates a stimulatory G-protein, which activates adenylyl cyclase, which converts ATP into cyclic AMP. cAMP activates protein kinase A. PKA phosphorylates hormone-sensitive lipase, which then hydrolyzes the second and third fatty acids off the stored triglyceride molecule. (The first fatty acid is removed by adipose triglyceride lipase, which is regulated separately.) The freed fatty acids leave the adipocyte, bind to circulating albumin, and travel to tissues — including muscle and liver — where they are oxidized for fuel.

Every step in this cascade is regulable. Every regulable step is a potential intervention point. The protocol exploits four of them simultaneously.

Four parallel inputs

β-adrenergic stimulation. The canonical input. Endogenous catecholamines hit the receptor, the cascade fires. Caffeine itself does not directly stimulate β receptors, but caffeine raises circulating catecholamines by central effects on the brain stem. EGCG (green tea extract) extends catecholamine half-life through COMT inhibition, amplifying the signal at every β receptor. Synephrine, a constituent of bitter orange, is a mild β3-agonist with selectivity for adipose-resident receptors.

Phosphodiesterase inhibition. Caffeine and other methylxanthines inhibit phosphodiesterase, the enzyme that breaks down cAMP. With PDE inhibited, cAMP that has been produced lingers longer at active concentration, prolonging the lipolytic signal. The effect compounds with anything that produced the cAMP in the first place — adrenergic, β3, forskolin — making caffeine a universal amplifier in the lipolysis stack.

α2 antagonism. The α2 brake, when present, suppresses adenylyl cyclase even when β stimulation is firing. Yohimbine antagonizes α2 and removes this suppression. In high-α2-density depots — abdominal adipose specifically — this is the single most leverage-bearing input in the entire cascade. See the α2 disinhibition mechanism page for full detail.

Direct adenylyl cyclase activation. Forskolin, the active diterpene from Indian coleus, directly activates adenylyl cyclase without receptor mediation. It bypasses every regulatory layer upstream — receptor binding, G-protein coupling, α2 inhibition, β desensitization — and raises cAMP from below. This is the protocol's redundancy mechanism; even if yohimbine is unavailable or contraindicated, forskolin produces cAMP elevation in α2-suppressed depots that nothing else can reach.

Why four inputs instead of one

Single-input lipolysis stimulation runs into ceilings. β agonists desensitize their receptors with sustained use. PDE inhibitors are limited by enzyme availability. α2 antagonists hit hard contraindications in many users. Direct adenylyl cyclase activation works but its clinical effect size is modest in isolation. Each input alone produces partial cAMP elevation that the body's normal regulatory mechanisms can compensate against.

Four inputs simultaneously overwhelm the compensatory mechanisms. β stimulation elevates cAMP; PDE inhibition prevents the elevation from being immediately dissipated; α2 antagonism prevents the elevation from being suppressed; direct adenylyl cyclase activation raises the floor independent of all upstream regulation. The combined elevation is multiplicative rather than additive, and it produces the dramatic difference between an unsupplemented fasted cardio session (modest fat oxidation) and a Mobilize-stacked fasted cardio session (substantial fat oxidation in α2-dominant depots specifically).

Downstream considerations

Elevated cAMP and active HSL produce free fatty acid release into circulation. From there, two things can happen. The fatty acids can be transported into mitochondria (in muscle, liver, brown adipose) for β-oxidation, where they become CO₂, water, and ATP. Or they can re-esterify in tissues — including back into adipose — where they become stored triglyceride again.

The choice is determined by metabolic demand. If the body is burning fat for fuel — fasted state, low-intensity steady-state exercise, cold exposure — the freed fatty acids enter mitochondria and are oxidized. If the body is not burning fat for fuel — fed state, sedentary, high-intensity glycogen-burning exercise — the freed fatty acids re-esterify and the lipolysis was for nothing.

This is why the Mobilize window pairs the lipolysis stack with zone-2 cardio specifically. Zone 2 is the exercise intensity at which the highest absolute quantity of fat is oxidized per unit time. Combined with the lipolytic stack in the fasted state, zone-2 cardio is the most productive fat-oxidation modality available to most users.

L-carnitine in the stack provides the carnitine substrate that the mitochondrial fatty acid transport system requires. Without sufficient carnitine, freed fatty acids cannot enter the mitochondrion and re-esterification dominates. Carnitine is rate-limiting in users with carnitine deficiency, which is more common than typically appreciated.

Side-effect profile of strong cAMP elevation

cAMP is a universal second messenger; elevating it does not affect only adipocytes. Tissues throughout the body experience the elevation, producing the side-effect profile that limits dosing of every input in the stack: cardiovascular stimulation (tachycardia, modest blood pressure elevation), CNS stimulation (alertness, anxiety in sensitive users), and tremor or jitter at the higher dose ranges.

The protocol's calibration is set against these side effects. Lower doses produce less side effect at the cost of less lipolysis; higher doses produce more lipolysis at the cost of more side effect. Most users find their working range at modest dose levels — caffeine 150-200 mg, yohimbine 5-10 mg, EGCG 300-500 mg, forskolin 250 mg — where lipolytic effect is meaningful and side effects are manageable.

Related